Free Trial

Canaccord Genuity Group's Rating of Madrigal Pharmaceuticals on 11/4/2026

On November 4, 2026, Canaccord Genuity Group updated its outlook on Madrigal Pharmaceuticals (NASDAQ:MDGL) with the action "Boost Price Target", setting a price target of $633.00. MarketBeat All Access subscribers can view the full ratings details, 12-month ROI, historical price target changes, and related news coverage on this page.

unlock icon  Upgrade to MarketBeat All Access

This premium research tool is available to MarketBeat All Access subscribers only. Log in to your account or sign up below.

Already have an account? Log in here.

More Ratings from Canaccord Genuity Group Inc.

DateCompanyAction
11/13/2026
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
Lower Price Target
11/13/2026
YETI Holdings, Inc. stock logo
YETI
YETI
Lower Price Target
11/13/2026
Spire Global, Inc. stock logo
SPIR
Spire Global
Lower Price Target
11/13/2026
EZCORP, Inc. stock logo
EZPW
EZCORP
Lower Price Target
11/13/2026
Heartflow, Inc. stock logo
HTFL
Heartflow
Boost Price Target
11/13/2026
Sagimet Biosciences Inc. stock logo
SGMT
Sagimet Biosciences
Lower Price Target
More Ratings From Canaccord Genuity Group Inc.